GlassScriptPhysician profile
Whitney D Tope
NPI 1770506784
$274.95
in general payments reported to CMS, 2019-2025
12 companies · $80.28 in 2025
The $80.28 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.00 · 2021: $15.00 · 2022: $79.85 · 2023: $60.93 · 2024: $23.89 · 2025: $80.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $82.32 | 2022-2023 | |
| Amgen INC. | $30.00 | 2020-2021 | |
| Smith+Nephew, INC. | $23.89 | 2024 | Grafix Pl, Oasis |
| Novartis Pharmaceuticals Corporation | $22.81 | 2025 | |
| Ucb, INC. | $15.60 | 2023 | Cimzia |
| Regeneron Healthcare Solutions, INC. | $15.33 | 2022 | |
| Galderma Laboratories, L.P. | $15.27 | 2025 | Nemluvio |
| Abbvie INC. | $14.83 | 2023 | Skyrizi |
| Leo Pharma INC. | $14.22 | 2025 | Adbry |
| Lilly USA, LLC | $14.06 | 2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.92 | 2025 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $12.70 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Tope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.